Phospholipid remodeling and its derivatives are associated with COVID-19 severity
[Display omitted] Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging. We investigated the levels of...
Saved in:
Published in | Journal of allergy and clinical immunology Vol. 151; no. 5; pp. 1259 - 1268 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.05.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 0091-6749 1097-6825 1097-6825 |
DOI | 10.1016/j.jaci.2022.11.032 |
Cover
Abstract | [Display omitted]
Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.
We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.
We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.
Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.
Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19’s severity and pathogenesis. |
---|---|
AbstractList | Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.
We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.
We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.
Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.
Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19's severity and pathogenesis. Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.BACKGROUNDTimely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.OBJECTIVEWe investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.METHODSWe performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.RESULTSPhospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19's severity and pathogenesis.CONCLUSIONSignificant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19's severity and pathogenesis. [Display omitted] Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging. We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression. We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease. Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models. Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19’s severity and pathogenesis. |
Author | Liu, Xiaoyu Fang, Zhangfu Lu, Jiahua Xiao, Weimin Liu, Zhigang Yang, Jun Sun, Baoqing Cai, Zongwei Zhong, Nanshan Chen, Hua-Ling Wei, Juntong Guan, Li Xiao, Xiaojun Huang, Shau-Ku Sun, Xizhuo Chen, Jiaping |
Author_xml | – sequence: 1 givenname: Juntong orcidid: 0000-0002-6430-2038 surname: Wei fullname: Wei, Juntong organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China – sequence: 2 givenname: Xiaoyu surname: Liu fullname: Liu, Xiaoyu organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China – sequence: 3 givenname: Weimin surname: Xiao fullname: Xiao, Weimin organization: Shenzhen Academy of Metrology and Quality Inspection, Shenzhen, China – sequence: 4 givenname: Jiahua surname: Lu fullname: Lu, Jiahua organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China – sequence: 5 givenname: Li surname: Guan fullname: Guan, Li organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China – sequence: 6 givenname: Zhangfu surname: Fang fullname: Fang, Zhangfu organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China – sequence: 7 givenname: Jiaping surname: Chen fullname: Chen, Jiaping organization: Shenzhen Academy of Metrology and Quality Inspection, Shenzhen, China – sequence: 8 givenname: Baoqing surname: Sun fullname: Sun, Baoqing organization: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China – sequence: 9 givenname: Zongwei surname: Cai fullname: Cai, Zongwei organization: State Key Laboratory of Environmental and Biological Analysis, Department of Chemistry, Hong Kong Baptist University, Hong Kong, China – sequence: 10 givenname: Xizhuo surname: Sun fullname: Sun, Xizhuo organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China – sequence: 11 givenname: Hua-Ling surname: Chen fullname: Chen, Hua-Ling organization: National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli County, Taiwan – sequence: 12 givenname: Nanshan surname: Zhong fullname: Zhong, Nanshan organization: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China – sequence: 13 givenname: Zhigang surname: Liu fullname: Liu, Zhigang organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China – sequence: 14 givenname: Jun surname: Yang fullname: Yang, Jun email: 3244536@qq.com organization: Shenzhen Academy of Metrology and Quality Inspection, Shenzhen, China – sequence: 15 givenname: Xiaojun surname: Xiao fullname: Xiao, Xiaojun email: xiaojun1985918@126.com organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China – sequence: 16 givenname: Shau-Ku surname: Huang fullname: Huang, Shau-Ku email: skhuang1@gmail.com organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36736798$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUFrFDEYQINU7Lb6BzxIjl5mzJfMZCbiRVZbC4UqFK8hk3zjZp2drEl2Zf-9Wba99FAhEELe-yAvF-RsDjMS8hZYDQzkh3W9NtbXnHFeA9RM8BdkAUx1lex5e0YWjCmoZNeoc3KR0pqVs-jVK3IuZFeW6hfkx_dVSNtVmPzWOxpxExxOfv5Fzeyoz4k6jH5vst9joiYiNSkF601GR__6vKLLu583XypQNOG-oPnwmrwczZTwzcN-Se6vvt4vv1W3d9c3y8-3lW1ayJUww9jIFpTkTY92ECjGBhGhUwOAFZwPIw6qbR02ghklJevLXVPkwbRMXJL3p7HbGP7sMGW98cniNJkZwy5p3nUCQAoJBX33gO6GDTq9jX5j4kE_VihAfwJsDClFHLX1ubw5zDkaP2lg-hhcr_UxuD4G1wC6BC8qf6I-Tn9W-nSSsPTZe4w6WY-zRecj2qxd8M_rH5_otnyZt2b6jYf_yf8AGbKr8A |
CitedBy_id | crossref_primary_10_1016_j_celrep_2024_114913 crossref_primary_10_3390_metabo13111107 crossref_primary_10_1016_j_phymed_2024_155968 crossref_primary_10_1093_procel_pwae006 crossref_primary_10_1007_s43440_023_00517_w crossref_primary_10_1016_j_talanta_2023_125522 crossref_primary_10_3390_diseases12110285 crossref_primary_10_1002_ctm2_1440 crossref_primary_10_3389_fimmu_2024_1337208 crossref_primary_10_1111_cpr_13749 crossref_primary_10_1021_acs_jafc_3c05305 crossref_primary_10_17816_morph_628983 crossref_primary_10_1016_j_fochx_2023_100736 crossref_primary_10_3390_jcm12175478 crossref_primary_10_2147_JIR_S495227 crossref_primary_10_3390_ijms241713164 |
Cites_doi | 10.1016/S0021-9258(18)70453-5 10.1073/pnas.1815356116 10.3389/fmicb.2019.00753 10.1016/j.cels.2020.10.003 10.1038/s41591-020-0819-2 10.1194/jlr.M500054-JLR200 10.1194/jlr.D700041-JLR200 10.1164/rccm.201306-1014OC 10.1016/j.cell.2020.05.032 10.1152/ajpendo.00198.2020 10.4049/jimmunol.178.10.6540 10.1016/j.jprot.2011.06.023 10.1183/13993003.01526-2020 10.1016/j.plipres.2011.06.001 10.1183/09031936.00209412 10.1038/nrd1776 10.1016/j.prostaglandins.2009.04.009 10.1189/jlb.0507292 10.1504/IJEX.2020.108602 10.1161/ATVBAHA.112.249854 10.1183/13993003.01740-2016 10.1093/nsr/nwaa086 10.3389/fmolb.2020.00012 10.18632/aging.103000 10.3390/cells9020473 10.1001/jama.2020.2648 10.1016/j.cmet.2020.06.016 10.1016/j.jhazmat.2019.121451 10.1016/j.cell.2020.10.037 10.1038/s41574-020-0353-9 10.1097/CCM.0000000000004411 10.1038/s41392-021-00508-4 |
ContentType | Journal Article |
Copyright | 2023 American Academy of Allergy, Asthma & Immunology Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2023 American Academy of Allergy, Asthma & Immunology – notice: Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.jaci.2022.11.032 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6825 |
EndPage | 1268 |
ExternalDocumentID | 36736798 10_1016_j_jaci_2022_11_032 S0091674923001422 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 22106108; U1801286; 31770984; 81901634 funderid: https://doi.org/10.13039/501100001809 – fundername: Shenzhen Science and Technology grantid: KQTD20170331145453160 – fundername: Natural Science Foundation of Guangdong Province grantid: 2019A1515110407 funderid: https://doi.org/10.13039/501100003453 – fundername: China Postdoctoral Science Foundation grantid: 2021M690785 funderid: https://doi.org/10.13039/501100002858 – fundername: Key Science and Technology Project of grantid: JSGG20200225153031960 funderid: https://doi.org/10.13039/100020450 |
GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8F7 8FE 8FH 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN ADXHL AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LK8 LUGTX M27 M41 MO0 N4W N9A O-L O9- O9~ OAUVE OBH ODZKP OHH OHT OK0 OK1 OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSI SSZ T5K TEORI TWZ UGJ UNMZH UV1 WH7 WOW WUQ X7M XFW YOC YQI YQJ Z5R ZGI ZXP ZY1 ~02 ~G- ~KM AACTN RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 EFLBG |
ID | FETCH-LOGICAL-c451t-3abf465196248ecb3e3f4eee179b11c322bfeb955de430a966081794451ba503 |
IEDL.DBID | AIKHN |
ISSN | 0091-6749 1097-6825 |
IngestDate | Thu Sep 04 17:57:23 EDT 2025 Thu Apr 03 07:07:27 EDT 2025 Tue Jul 01 04:21:57 EDT 2025 Thu Apr 24 23:12:52 EDT 2025 Sun Apr 06 06:53:01 EDT 2025 Tue Aug 26 16:37:31 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | LPE PE O LPC 16:1 PC O APACHE II phospholipid ratio AUC COVID-19 SARS-CoV-2 PC FDR PE LPE 18:1 lipidomics LPC |
Language | English |
License | Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c451t-3abf465196248ecb3e3f4eee179b11c322bfeb955de430a966081794451ba503 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6430-2038 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9891787 |
PMID | 36736798 |
PQID | 2773116361 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2773116361 pubmed_primary_36736798 crossref_citationtrail_10_1016_j_jaci_2022_11_032 crossref_primary_10_1016_j_jaci_2022_11_032 elsevier_sciencedirect_doi_10_1016_j_jaci_2022_11_032 elsevier_clinicalkey_doi_10_1016_j_jaci_2022_11_032 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2023 2023-05-00 20230501 |
PublicationDateYYYYMMDD | 2023-05-01 |
PublicationDate_xml | – month: 05 year: 2023 text: May 2023 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of allergy and clinical immunology |
PublicationTitleAlternate | J Allergy Clin Immunol |
PublicationYear | 2023 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Wu, McGoogan (bib2) 2020; 323 Yu, Sun, Fang, Zhao, Liu, Li (bib3) 2020; 56 Cheng, Chien, Lai, Li, Lin, Ho (bib4) 2020; 9 Yilmaz, Ercan, Akduman, Ozilgen (bib5) 2020; 32 Su, Chen, Yuan, Lausted, Choi, Dai (bib14) 2020; 183 Kyle, Burnum-Johnson, Wendler, Eisfeld, Halfmann, Watanabe (bib6) 2019; 116 Shen, Yi, Sun, Bi, Du, Zhang (bib9) 2020; 182 Zou, Li, Fang, Hu, Bian, Ling (bib22) 2020; 48 Makide, Kitamura, Sato, Okutani, Aoki (bib25) 2009; 89 Wu, Shu, Yang, Song, Zhang, Yao (bib10) 2020; 7 Frisardi, Panza, Seripa, Farooqui, Farooqui (bib26) 2011; 50 Wang, Li, Lu, Huang (bib19) 2020; 12 Gauster, Rechberger, Sovic, Horl, Steyrer, Sattler (bib24) 2005; 46 Bornstein, Dalan, Hopkins, Mingrone, Boehm (bib20) 2020; 16 Ojala, Hirvonen, Hermansson, Somerharju, Parkkinen (bib32) 2007; 82 Wei, Li, Xiang, Song, Liu, Jiang (bib16) 2020; 390 Frasch, Zemski-Berry, Murphy, Borregaard, Henson, Bratton (bib28) 2007; 178 Matyash, Liebisch, Kurzchalia, Shevchenko, Schwudke (bib15) 2008; 49 Polonis, Wawrzyniak, Daghir-Wojtkowiak, Szyndler, Chrostowska, Melander (bib18) 2020; 7 Park, Lee, Berdyshev, Nyenhuis, Du, Fu (bib30) 2013; 188 Korakas, Ikonomidis, Kousathana, Balampanis, Kountouri, Raptis (bib21) 2020; 319 Lands (bib31) 1958; 231 Gonçalves, Edsfeldt, Young, Grufman, Berg, Björkbacka (bib23) 2012; 32 Larsson, Lundstrom, Pinto, Rankin, Karimpour, Blomberg (bib29) 2014; 43 Queiroz, Pinto, Lima, Giovanetti, de Jesus, Xavier (bib7) 2019; 10 Reinke, Gallart-Ayala, Gomez, Checa, Fauland, Naz (bib8) 2017; 49 Overmyer, Shishkova, Miller, Balnis, Bernstein, Peters-Clarke (bib12) 2021; 12 Li, Hou, Zhou, Wang, Tun, Zhu (bib11) 2021; 6 Song, Lam, Fan, Cao, Wang, Tian (bib13) 2020; 32 Del Boccio, Pieragostino, Di Ioia, Petrucci, Lugaresi, De Luca (bib27) 2011; 74 Thevarajan, Nguyen, Koutsakos, Druce, Caly, van de Sandt (bib1) 2020; 26 Wenk (bib17) 2005; 4 Wu (10.1016/j.jaci.2022.11.032_bib2) 2020; 323 Li (10.1016/j.jaci.2022.11.032_bib11) 2021; 6 Gonçalves (10.1016/j.jaci.2022.11.032_bib23) 2012; 32 Queiroz (10.1016/j.jaci.2022.11.032_bib7) 2019; 10 Song (10.1016/j.jaci.2022.11.032_bib13) 2020; 32 Wu (10.1016/j.jaci.2022.11.032_bib10) 2020; 7 Polonis (10.1016/j.jaci.2022.11.032_bib18) 2020; 7 Gauster (10.1016/j.jaci.2022.11.032_bib24) 2005; 46 Su (10.1016/j.jaci.2022.11.032_bib14) 2020; 183 Park (10.1016/j.jaci.2022.11.032_bib30) 2013; 188 Lands (10.1016/j.jaci.2022.11.032_bib31) 1958; 231 Cheng (10.1016/j.jaci.2022.11.032_bib4) 2020; 9 Wei (10.1016/j.jaci.2022.11.032_bib16) 2020; 390 Zou (10.1016/j.jaci.2022.11.032_bib22) 2020; 48 Del Boccio (10.1016/j.jaci.2022.11.032_bib27) 2011; 74 Shen (10.1016/j.jaci.2022.11.032_bib9) 2020; 182 Reinke (10.1016/j.jaci.2022.11.032_bib8) 2017; 49 Wenk (10.1016/j.jaci.2022.11.032_bib17) 2005; 4 Yilmaz (10.1016/j.jaci.2022.11.032_bib5) 2020; 32 Yu (10.1016/j.jaci.2022.11.032_bib3) 2020; 56 Larsson (10.1016/j.jaci.2022.11.032_bib29) 2014; 43 Ojala (10.1016/j.jaci.2022.11.032_bib32) 2007; 82 Korakas (10.1016/j.jaci.2022.11.032_bib21) 2020; 319 Matyash (10.1016/j.jaci.2022.11.032_bib15) 2008; 49 Frisardi (10.1016/j.jaci.2022.11.032_bib26) 2011; 50 Thevarajan (10.1016/j.jaci.2022.11.032_bib1) 2020; 26 Kyle (10.1016/j.jaci.2022.11.032_bib6) 2019; 116 Overmyer (10.1016/j.jaci.2022.11.032_bib12) 2021; 12 Makide (10.1016/j.jaci.2022.11.032_bib25) 2009; 89 Wang (10.1016/j.jaci.2022.11.032_bib19) 2020; 12 Bornstein (10.1016/j.jaci.2022.11.032_bib20) 2020; 16 Frasch (10.1016/j.jaci.2022.11.032_bib28) 2007; 178 |
References_xml | – volume: 48 start-page: E657 year: 2020 end-page: E665 ident: bib22 article-title: Acute Physiology and Chronic Health Evaluation II Score as a predictor of hospital mortality in patients of coronavirus disease 2019 publication-title: Crit Care Med – volume: 182 start-page: 59 year: 2020 end-page: 72.e15 ident: bib9 article-title: Proteomic and metabolomic characterization of COVID-19 patient sera publication-title: Cell – volume: 323 start-page: 1239 year: 2020 end-page: 1242 ident: bib2 article-title: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention publication-title: JAMA – volume: 82 start-page: 1501 year: 2007 end-page: 1509 ident: bib32 article-title: Acyl chain–dependent effect of lysophosphatidylcholine on human neutrophils publication-title: J Leukoc Biol – volume: 9 start-page: 473 year: 2020 ident: bib4 article-title: Metabolic reprogramming of host cells in response to enteroviral infection publication-title: Cells – volume: 50 start-page: 313 year: 2011 end-page: 330 ident: bib26 article-title: Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology publication-title: Prog Lipid Res – volume: 89 start-page: 135 year: 2009 end-page: 139 ident: bib25 article-title: Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol publication-title: Prostaglandins Other Lipid Mediat – volume: 390 year: 2020 ident: bib16 article-title: Metabolomics and lipidomics study unveils the impact of polybrominated diphenyl ether-47 on breast cancer mice publication-title: J Hazard Mater – volume: 74 start-page: 2826 year: 2011 end-page: 2836 ident: bib27 article-title: Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis publication-title: J Proteomics – volume: 10 start-page: 753 year: 2019 ident: bib7 article-title: Lipidomic analysis reveals serum alteration of plasmalogens in patients infected with Zika virus publication-title: Front Microbiol – volume: 49 year: 2017 ident: bib8 article-title: Metabolomics analysis identifies different metabotypes of asthma severity publication-title: Eur Respir J – volume: 26 year: 2020 ident: bib1 article-title: Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 publication-title: Nat Med – volume: 116 start-page: 3919 year: 2019 end-page: 3928 ident: bib6 article-title: Plasma lipidome reveals critical illness and recovery from human Ebola virus disease publication-title: Proc Natl Acad Sci U S A – volume: 4 start-page: 594 year: 2005 end-page: 610 ident: bib17 article-title: The emerging field of lipidomics publication-title: Nat Rev Drug Discov – volume: 12 start-page: 6049 year: 2020 end-page: 6057 ident: bib19 article-title: Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis publication-title: Aging (Albany NY) – volume: 7 start-page: 1157 year: 2020 end-page: 1168 ident: bib10 article-title: Plasma metabolomic and lipidomic alterations associated with COVID-19 publication-title: Natl Sci Rev – volume: 319 start-page: E105 year: 2020 end-page: E109 ident: bib21 article-title: Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes publication-title: Am J Physiol Endocrinol Metab – volume: 188 start-page: 928 year: 2013 end-page: 940 ident: bib30 article-title: Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation publication-title: Am J Respir Crit Care Med – volume: 16 start-page: 297 year: 2020 end-page: 298 ident: bib20 article-title: Endocrine and metabolic link to coronavirus infection publication-title: Nat Rev Endocrinol – volume: 56 year: 2020 ident: bib3 article-title: Distinct features of SARS-CoV-2–specific IgA response in COVID-19 patients publication-title: Eur Respir J – volume: 6 start-page: 155 year: 2021 ident: bib11 article-title: Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery publication-title: Signal Transduct Target Ther – volume: 178 start-page: 6540 year: 2007 end-page: 6548 ident: bib28 article-title: Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A publication-title: J Immunol – volume: 32 start-page: 1505 year: 2012 end-page: 1512 ident: bib23 article-title: Evidence supporting a key role of Lp-PLA2–generated lysophosphatidylcholine in human atherosclerotic plaque inflammation publication-title: Arterioscler Thromb Vasc Biol – volume: 49 start-page: 1137 year: 2008 end-page: 1146 ident: bib15 article-title: Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics publication-title: J lipid Res – volume: 46 start-page: 1517 year: 2005 end-page: 1525 ident: bib24 article-title: Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine publication-title: J Lipid Res – volume: 231 start-page: 883 year: 1958 end-page: 888 ident: bib31 article-title: Metabolism of glycerolipides; a comparison of lecithin and triglyceride synthesis publication-title: J Biol Chem – volume: 32 start-page: 314 year: 2020 end-page: 327 ident: bib5 article-title: Energetic and exergetic costs of COVID-19 infection on the body of a patient publication-title: Int J Exergy – volume: 12 start-page: 23 year: 2021 ident: bib12 article-title: Large-Scale multi-omic analysis of COVID-19 severity publication-title: Cell Syst – volume: 32 start-page: 188 year: 2020 ident: bib13 article-title: Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis publication-title: Cell Metab – volume: 183 start-page: 1479 year: 2020 ident: bib14 article-title: Multi-Omics resolves a sharp disease-state shift between mild and moderate COVID-19 publication-title: Cell – volume: 43 start-page: 453 year: 2014 end-page: 463 ident: bib29 article-title: Lipid mediator profiles differ between lung compartments in asthmatic and healthy humans publication-title: Eur Respir J – volume: 7 start-page: 12 year: 2020 ident: bib18 article-title: Metabolomic signature of early vascular aging (EVA) in hypertension publication-title: Front Mol Biosci – volume: 231 start-page: 883 year: 1958 ident: 10.1016/j.jaci.2022.11.032_bib31 article-title: Metabolism of glycerolipides; a comparison of lecithin and triglyceride synthesis publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)70453-5 – volume: 116 start-page: 3919 year: 2019 ident: 10.1016/j.jaci.2022.11.032_bib6 article-title: Plasma lipidome reveals critical illness and recovery from human Ebola virus disease publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1815356116 – volume: 10 start-page: 753 year: 2019 ident: 10.1016/j.jaci.2022.11.032_bib7 article-title: Lipidomic analysis reveals serum alteration of plasmalogens in patients infected with Zika virus publication-title: Front Microbiol doi: 10.3389/fmicb.2019.00753 – volume: 12 start-page: 23 year: 2021 ident: 10.1016/j.jaci.2022.11.032_bib12 article-title: Large-Scale multi-omic analysis of COVID-19 severity publication-title: Cell Syst doi: 10.1016/j.cels.2020.10.003 – volume: 26 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib1 article-title: Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 publication-title: Nat Med doi: 10.1038/s41591-020-0819-2 – volume: 46 start-page: 1517 year: 2005 ident: 10.1016/j.jaci.2022.11.032_bib24 article-title: Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine publication-title: J Lipid Res doi: 10.1194/jlr.M500054-JLR200 – volume: 49 start-page: 1137 year: 2008 ident: 10.1016/j.jaci.2022.11.032_bib15 article-title: Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics publication-title: J lipid Res doi: 10.1194/jlr.D700041-JLR200 – volume: 188 start-page: 928 year: 2013 ident: 10.1016/j.jaci.2022.11.032_bib30 article-title: Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201306-1014OC – volume: 182 start-page: 59 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib9 article-title: Proteomic and metabolomic characterization of COVID-19 patient sera publication-title: Cell doi: 10.1016/j.cell.2020.05.032 – volume: 319 start-page: E105 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib21 article-title: Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00198.2020 – volume: 178 start-page: 6540 year: 2007 ident: 10.1016/j.jaci.2022.11.032_bib28 article-title: Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A publication-title: J Immunol doi: 10.4049/jimmunol.178.10.6540 – volume: 74 start-page: 2826 year: 2011 ident: 10.1016/j.jaci.2022.11.032_bib27 article-title: Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis publication-title: J Proteomics doi: 10.1016/j.jprot.2011.06.023 – volume: 56 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib3 article-title: Distinct features of SARS-CoV-2–specific IgA response in COVID-19 patients publication-title: Eur Respir J doi: 10.1183/13993003.01526-2020 – volume: 50 start-page: 313 year: 2011 ident: 10.1016/j.jaci.2022.11.032_bib26 article-title: Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology publication-title: Prog Lipid Res doi: 10.1016/j.plipres.2011.06.001 – volume: 43 start-page: 453 year: 2014 ident: 10.1016/j.jaci.2022.11.032_bib29 article-title: Lipid mediator profiles differ between lung compartments in asthmatic and healthy humans publication-title: Eur Respir J doi: 10.1183/09031936.00209412 – volume: 4 start-page: 594 year: 2005 ident: 10.1016/j.jaci.2022.11.032_bib17 article-title: The emerging field of lipidomics publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1776 – volume: 89 start-page: 135 year: 2009 ident: 10.1016/j.jaci.2022.11.032_bib25 article-title: Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol publication-title: Prostaglandins Other Lipid Mediat doi: 10.1016/j.prostaglandins.2009.04.009 – volume: 82 start-page: 1501 year: 2007 ident: 10.1016/j.jaci.2022.11.032_bib32 article-title: Acyl chain–dependent effect of lysophosphatidylcholine on human neutrophils publication-title: J Leukoc Biol doi: 10.1189/jlb.0507292 – volume: 32 start-page: 314 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib5 article-title: Energetic and exergetic costs of COVID-19 infection on the body of a patient publication-title: Int J Exergy doi: 10.1504/IJEX.2020.108602 – volume: 32 start-page: 1505 year: 2012 ident: 10.1016/j.jaci.2022.11.032_bib23 article-title: Evidence supporting a key role of Lp-PLA2–generated lysophosphatidylcholine in human atherosclerotic plaque inflammation publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.112.249854 – volume: 49 year: 2017 ident: 10.1016/j.jaci.2022.11.032_bib8 article-title: Metabolomics analysis identifies different metabotypes of asthma severity publication-title: Eur Respir J doi: 10.1183/13993003.01740-2016 – volume: 7 start-page: 1157 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib10 article-title: Plasma metabolomic and lipidomic alterations associated with COVID-19 publication-title: Natl Sci Rev doi: 10.1093/nsr/nwaa086 – volume: 7 start-page: 12 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib18 article-title: Metabolomic signature of early vascular aging (EVA) in hypertension publication-title: Front Mol Biosci doi: 10.3389/fmolb.2020.00012 – volume: 12 start-page: 6049 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib19 article-title: Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis publication-title: Aging (Albany NY) doi: 10.18632/aging.103000 – volume: 9 start-page: 473 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib4 article-title: Metabolic reprogramming of host cells in response to enteroviral infection publication-title: Cells doi: 10.3390/cells9020473 – volume: 323 start-page: 1239 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib2 article-title: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention publication-title: JAMA doi: 10.1001/jama.2020.2648 – volume: 32 start-page: 188 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib13 article-title: Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis publication-title: Cell Metab doi: 10.1016/j.cmet.2020.06.016 – volume: 390 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib16 article-title: Metabolomics and lipidomics study unveils the impact of polybrominated diphenyl ether-47 on breast cancer mice publication-title: J Hazard Mater doi: 10.1016/j.jhazmat.2019.121451 – volume: 183 start-page: 1479 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib14 article-title: Multi-Omics resolves a sharp disease-state shift between mild and moderate COVID-19 publication-title: Cell doi: 10.1016/j.cell.2020.10.037 – volume: 16 start-page: 297 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib20 article-title: Endocrine and metabolic link to coronavirus infection publication-title: Nat Rev Endocrinol doi: 10.1038/s41574-020-0353-9 – volume: 48 start-page: E657 year: 2020 ident: 10.1016/j.jaci.2022.11.032_bib22 article-title: Acute Physiology and Chronic Health Evaluation II Score as a predictor of hospital mortality in patients of coronavirus disease 2019 publication-title: Crit Care Med doi: 10.1097/CCM.0000000000004411 – volume: 6 start-page: 155 year: 2021 ident: 10.1016/j.jaci.2022.11.032_bib11 article-title: Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-021-00508-4 |
SSID | ssj0009389 |
Score | 2.5027132 |
Snippet | [Display omitted]
Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are... Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1259 |
SubjectTerms | COVID-19 Humans lipidomics LPC 16:1 LPE 18:1 Lysophosphatidylcholines - metabolism phospholipid ratio Phospholipids - metabolism |
Title | Phospholipid remodeling and its derivatives are associated with COVID-19 severity |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0091674923001422 https://dx.doi.org/10.1016/j.jaci.2022.11.032 https://www.ncbi.nlm.nih.gov/pubmed/36736798 https://www.proquest.com/docview/2773116361 |
Volume | 151 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEBapA6WX0nfdR1Cht6LEenp1DG6D05K0hbTkJvSYJRvK2thOjvntHe1qXXpICr0uO0jMaD59kuZByHuDlMN7OWUqmAlTPibmda1YbUVIOkJlunvIk1Mz_6E-n-vzHTIbcmFyWGXB_h7TO7QuXw6KNg-WTZNzfG0OoUeGknm-QBzeFdIaPSK7h8df5qd_au_KqmfBlrMsUHJn-jCvSx8bPCYKsZ-LeUpx2_50G__s9qGjR-RhIZD0sJ_jY7ID7RNy_6Q8kT8l379dLNZLxLRm2SS6gq7VDe5P1LeJNps1Tbjmrrty32vqV0B9MRAkmi9l6ezrz-OPjFuKc4Lc2u4ZOTv6dDabs9I3gUWl-YZJH-rc4twaoSqIQYKsFQCg7wXOI7pwqCFYrRMoOfG5PmeV_RKFg9cT-ZyM2kULLwk1VfQgvDGqQuaCh4lkfcovjxOAKiYYEz4oy8VSUzy3tvjlhuCxS5cV7LKC8bDhUMFj8mErs-wratz5txxs4IZcUUQ3h4B_p5TeSv21mv4p924ws0M3y28nvoXF1dqJ6VRy5K6Gj8mL3v7b2cscGze11av_HPU1eZCb2PdhlG_IaLO6grdIdTZhj9zbv-F7ZUH_BmMD-sQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELaqIgEX1PIM5WEkbshtdv3Y9RGFVik0BaSAerP8mFW3QpsoSTny25nZRxCHFonryqO1Zjzjz_Y3M4y9NQg5vJeFUMGMhfIxCa8rJSqbh6QjlKa9h5ydm-k39fFCX-ywyZALQ7TKPvZ3Mb2N1v2Xo16bR8u6phxfSxR6RCiE83OMw3eUlgXx-g5__eF5WFl2GNhmgob3mTMdyevKxxoPiXl-SKU8ZX7T7nQT-mx3oZM99qCHj_x9N8N9tgPNQ3Z31j-QP2Jfv1wu1kuMaPWyTnwFbaMb3J24bxKvN2uecMX9bIt9r7lfAfe9eSBxupLlk8_fTz-IzHKcE1Bju8dsfnI8n0xF3zVBRKWzjZA-VNTg3JpclRCDBFkpAEDPC1kW0YFDBcFqnUDJsafqnCV5JQoHr8fyCdttFg08Y9yU0UPujVEl4hY8SiTrE707jgHKmGDEskFZLvYVxamxxQ83UMeuHCnYkYLxqOFQwSP2biuz7Opp3DpaDjZwQ6YoxjaH4f5WKb2V-mst_VPuzWBmh05GLye-gcX12uVFITNEriYbsaed_bezl8SMK2z5_D__-prdm85nZ-7s9PzTAbtP7ew7QuULtrtZXcNLBD2b8Kpd1L8BfcH7jw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phospholipid+remodeling+and+its+derivatives+are+associated+with+COVID-19+severity&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Wei%2C+Juntong&rft.au=Liu%2C+Xiaoyu&rft.au=Xiao%2C+Weimin&rft.au=Lu%2C+Jiahua&rft.date=2023-05-01&rft.issn=1097-6825&rft.eissn=1097-6825&rft.volume=151&rft.issue=5&rft.spage=1259&rft_id=info:doi/10.1016%2Fj.jaci.2022.11.032&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon |